Selected article for: "fatality rate and ribavirin treatment"

Author: Takayama-Ito, Mutsuyo; Saijo, Masayuki
Title: Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
  • Document date: 2020_2_11
  • ID: 0czu600e_25
    Snippet: Since then, a considerable number of studies regarding its epidemiological and virological characteristics have been conducted. Ribavirin, one of a broad-spectrum antiviral drug (Beaucourt and Vignuzzi, 2014) , is recommended for patients with SFTS in China, and it has been used to treat a considerable number of patients (Ministry of Health People's Republic of China, 2011) . The in vitro and in vivo studies on ribavirin (Shimojima et al., 2014 (.....
    Document: Since then, a considerable number of studies regarding its epidemiological and virological characteristics have been conducted. Ribavirin, one of a broad-spectrum antiviral drug (Beaucourt and Vignuzzi, 2014) , is recommended for patients with SFTS in China, and it has been used to treat a considerable number of patients (Ministry of Health People's Republic of China, 2011) . The in vitro and in vivo studies on ribavirin (Shimojima et al., 2014 (Shimojima et al., , 2015 Tani et al., 2016; Lee et al., 2017) showed the considerable effect. The results of the clinical study conducted by Liu et al. (2013) , which showed that ribavirin did not reduce the fatality rate of patients with SFTS, discouraged us from considering ribavirin treatment for treating patients with SFTS. However, Li et al. (2018) reported that ribavirin is effective for early-stage patients with a low viral titer or for the pretreatment of exposed individuals. Nevertheless, in cases of ribavirin administration, patients should be intensely monitored because of the possible adverse events induced by ribavirin such as anemia and hyperamylasemia (Lu et al., 2015) .

    Search related documents:
    Co phrase search for related documents